---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-22-000007"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2022-03-04T23:59:59+00:00"
generated_at: "2026-06-27T01:29:17.287844+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro Biosystems FY2021 commercial revenue up 54% to $21.6M; net loss $73.5M

## Summary
- FY2021 total revenue $23.2M vs $16.1M; commercial revenue $21.6M (+54%); net loss $73.5M vs $37.1M.
- Q4 2021 total revenue $5.2M flat YoY; commercial revenue $4.9M; recurring revenue $2.3M (+91%).
- FY2022 commercial revenue guidance reaffirmed at $27M-$32M (25-50% growth).
- Cash, cash equivalents and investments $203.5M, no debt.
- Placed 29 new systems FY2021; cumulative placed 116, validated 84.

## SEC filing metadata
- accession: 0001380106-22-000007
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2022-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010622000007/0001380106-22-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010622000007/c106-20220304x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-22-000007
- JSON: https://secwatch.observer/filing/0001380106-22-000007.json
- Plain text: https://secwatch.observer/filing/0001380106-22-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.